IMNM News and Press, Immunome Inc.

2024-06-27 14:14:36 ET Summary Top-line data from Part B of phase 3 RINGSIDE study, using AL102 for the treatment of patients with desmoid tumors, expected 2nd half of 2025. The global desmoid tumor market is projected to grow to $5.49 billion by 2032. IM-1021 is an antibody-d...

2024-06-27 11:27:19 ET Summary Immunome, Inc. stock surged over 400% post-merger and management changes but has since dropped over 60% as initial enthusiasm has waned. The company's new CEO has drawn attention to the company, which has one asset, AL102, in clinical evaluation for ...

2024-06-27 08:37:52 ET More on Immunome Immunome: An Oncology Powerhouse In The Making Seeking Alpha’s Quant Rating on Immunome Read the full article on Seeking Alpha For further details see: Immunome names Tsai as chief technical officer

Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Tsai, PhD, as Chief Technical Officer. Dr. Tsai has nearly three decades of experience in product development, proces...

2024-05-21 22:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 mi...

2024-05-17 08:08:48 ET More on Immunome Immunome: An Oncology Powerhouse In The Making Seeking Alpha’s Quant Rating on Immunome Historical earnings data for Immunome Financial information for Immunome Read the full article on Seeking Alpha ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Ope...

2024-05-14 13:54:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ: IMNM ) just reported results for the first quarter of 2024. Immunome reported earnings per share of -34 cents. This was above the analyst estimate for EP...

2024-05-14 10:48:34 ET More on Immunome Immunome: An Oncology Powerhouse In The Making Seeking Alpha’s Quant Rating on Immunome Historical earnings data for Immunome Financial information for Immunome Read the full article on Seeking Alpha ...